Bio Career Breakfast from Lek is Golden Practice 2016
- Lek was awarded the best Golden Practice 2016 Award for the Bio Career Breakfast project, bestowed as part of the Golden Thread project.
- The Golden Practice Award is bestowed to the boldest, most innovative and efficient practice, project, action, idea or activity focusing on organisational shifts and collective progress.
- Lek first received the Golden Practice Award in 2014 for the organisation and execution of the Regional BioCamp.
At yesterday’s Golden Thread Award ceremony, Lek received the prestigious Golden Practice Award. Among the 19 submissions participating, the jury recognised the uniqueness and excellence of the Bio Career Breakfast that Lek organised in 2017 for the second time in a row.
The Bio Career Breakfast is Lek’s unique response to the modern migration trend among the highly educated workforce and an example of an innovative initiative for creating a stimulating work environment for the top Slovenian experts. »A high-quality, educated and committed employees are a key strategic advantage in the pharmaceutical industry. Lek is aware of this, therefore we pay a lot of attention to creating a stimulating and development-oriented work environment. The Bio Career Breakfast is one of the human resource practices for pursuing this goal at Lek. Its uniqueness lies in the fact that it turns a nation-wide trend of »brain drain« in the opposite direction. The event is namely aimed at the top Slovenian experts working abroad to entice them to return to their home environment. This particular human resource practice is therefore not important for Lek only, but also brings important benefits to the wider Slovenian economic and social environment,« highlighted Špela Bernhard, who developed Bio Career Breakfast.
The Golden Practice Award is bestowed by the Slovenian media Dnevnik, the organizer of the media-research project The Golden Thread. In the reasoning of the award, the organiser emphasised: »In recent years, statistics in Slovenia show a growing trend in migration abroad as well as a brain drain. Lek challenged itself 'to bring the brains back' and enable the talents a professional development and the use of knowledge and skills they obtained abroad. Last year, more than 90 experts attended the event. Lek conducted interviews with more than 30 candidates and in the same year recruited ten experts. This year, the event attracted more than 70 new participants, of whom more than 30 became candidates in the interview process and some of them are now in the final stage of an employment agreement.«
Lek received the Golden Practice Award for the second time in a row. Three years ago it was awarded for the organisation and execution of the Regional BioCamp forum. Click here to read more.
Lek, a Sandoz company, is one of the key pillars of the second-largest generic pharmaceutical company globally. Its role within Sandoz is to act as: a leading global development center for technologically demanding products and technologies; a key global manufacturing center for active pharmaceutical ingredients and medicines; a competence center for the development of vertically integrated products; a Sandoz competence center in the field of development and manufacturing of biosimilar active ingredients and products; a supply center for the markets of Central and Eastern Europe (CEE), South East Europe (SEE) and the Commonwealth of Independent States (CIS), and is responsible for marketing and sales of Sandoz products on the Slovenian market. For further information, please visit www.lek.si.
Sandoz is a global leader in generic and biosimilar pharmaceuticals. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people’s lives. We contribute to society’s ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our portfolio of approximately 1000 molecules, covering all major therapeutic areas, accounted for 2015 sales of USD 10.1 billion. In 2015, our products reached more than 500 million patients and we aspire to reach one billion. Sandoz is headquartered in Holzkirchen, in Germany’s Greater Munich area.
Sandoz is on Twitter. Sign up to follow @Sandoz_global at http://twitter.com/Sandoz_Global (link is external).
For further details visit www.sandoz.com/makingaccesshappen
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2016, the Group achieved net sales of USD 48.5 billion, while R&D throughout the Group amounted to approximately USD 9 billion (USD 8.4 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in more than 155 countries around the world. For more information, please visit www.novartis.com.
This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.
For additional information contact:
Lek Pharmaceuticals d. d.
Phone: +386 1 580 22 43
Fax: +386 1 580 24 32